Глобальный рынок острого респираторного дистресс-синдрома (ОРДС) – тенденции отрасли и прогноз до 2030 года

Анализ и размер рынка острого респираторного дистресс-синдрома (ОРДС)

Острый респираторный дистресс-синдром (ОРДС) поражает около трети или (33%) госпитализированных пациентов, согласно исследованию под названием «Острый респираторный дистресс-синдром при COVID-19: потенциальные причины и терапевтическая терапия», опубликованному в журнале Pneumonia в декабре 2021 года. Кроме того, из пациентов с COVID-19, поступивших в отделение интенсивной терапии, 75% (или почти 3/4) имеют ОРДС. Прогноз и уровень летальности для пациентов с ОРДС и COVID-19 неблагоприятный. В результате COVID-19 оказал резкое влияние на рынок острого респираторного дистресса. В результате, по мере того, как становится больше коек для лечения пациентов с ОРДС, больше больниц будут поддерживать расширение сегмента в течение прогнозируемого периода.

Компания Data Bridge Market Research анализирует, что рынок острого респираторного дистресс-синдрома (ОРДС), который в 2022 году оценивался в 129 655,84 млн долларов США, к 2030 году, как ожидается, достигнет 279 956,55 млн долларов США при среднегодовом темпе роста 10,1% в прогнозируемый период с 2023 по 2030 год. Помимо информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные компанией Data Bridge Market Research, также включают в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ воронки продаж, анализ цен и нормативно-правовую базу.

Острый респираторный дистресс-синдром (ОРДС): масштаб и сегментация рынка  

Определение рынка

Острый респираторный дистресс-синдром (ОРДС) — это потенциально смертельное повреждение легких, которое приводит к просачиванию жидкости в легкие. Большинство людей, у которых развивается ОРДС, уже находятся в больнице, восстанавливаясь после травмы или проходя лечение от такого заболевания, как COVID-19. Заболевание обычно развивается, когда жидкости скапливаются в крошечных эластичных воздушных мешочках или альвеолах легких. В результате этого накопления жидкости в кровоток поступает меньше кислорода. В результате органы лишаются достаточного количества кислорода для нормальной работы. В течение нескольких часов или дней после первоначальной травмы или инфекции у людей с другими заболеваниями разовьется ОРДС. В зависимости от тяжести состояния шансы пациента на выживание увеличиваются с возрастом.

Динамика рынка острого респираторного дистресс-синдрома (ОРДС)

Драйверы

• Больше запусков продуктов

Проводится ряд государственных кампаний по повышению осведомленности, чтобы информировать больше людей о спектре доступных диагностик и методов лечения. Крупные компании на рынке представили несколько товаров с превосходными возможностями. Например, в мае 2021 года компания Medtronic объявила о выпуске системы мониторинга дыхательных путей SonarMed. Акустическая технология используется этим устройством мониторинга для обнаружения окклюзии эндотрахеальной трубки. Это ускоряет расширение рынка.

• Растущая потребность в лечении ОРДС

The need for ARDS treatment is generated by an increase in hospital admissions and admissions to the critical care unit, which propels the market's expansion. 18.4% of patients with acute respiratory distress syndrome required re-hospitalization, according to a study titled "Acute respiratory distress syndrome readmissions: A countrywide cross-sectional analysis of epidemiology and costs of care" that was published in the PLOS One Journal in January 2022. Additionally, according to data from the Australian Institute of Health and Welfare published in May 2022, there were 11.8 million hospital admissions in 2020–21, an increase of 6.3% from 2019–20. Out of 11.8 million admissions, it was also reported that 7.0% of hospitalizations involved an ICU stay, 3.8% of hospitalizations involved respiratory disease, and 10.3% of hospitalizations had a separation mode indicating the patient passed away in the hospital. The market segment is anticipated to grow as a result of the rising number of admissions into emergency critical care, which creates a need for ARDS treatment.

Opportunities

• Increased Demand of Diagnosis

The market is expanding due to the increasing need for diagnoses. As many patients require several diagnoses in order for the treatment to be finished in a timely manner, the diagnosis sector is predicted to dominate the market. As a result, the market has huge opportunity.

Restraints/Challenges

• Lack of Skilled Professionals

The development of the global respiratory distress syndrome treatment market during the forecast period may be restrained by a lack of qualified specialists who are ignorant of the available treatment options for this illness.

• Increasing Cost of Treatment Therapeutics

Despite the fact that disease prevalence is rising, drug prices are also rising at the same time. These escalating treatment costs are restraining the market's expansion.

This acute respiratory distress syndrome (ARDS) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acute respiratory distress syndrome (ARDS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Acute Respiratory Distress Syndrome (ARDS) Market

The COVID-19 pandemic epidemic affected the global economy. Respiratory illnesses such as pneumonia and acute respiratory distress syndrome gradually developed due to the disease's extreme infectiousness and contagiousness throughout the pandemic and even in the post-pandemic era. As a result, the COVID-19 pandemic led to significant rise in the global market for treatments for respiratory distress syndrome.

Recent Developments

• In 2021, SonarMed airway monitoring system's introduction was announced by Medtronic. To check for endotracheal tube obstruction, the system uses acoustic technology. The company's product line has grown as a result of this.
• In 2020, The SARS-CoV-2 fast antibody test was available, according to F. Hoffman-La Roche Ltd. Together with SD Biosenseor, Inc., the experiment was started. The company's product line has grown as a result of this.

Acute Respiratory Distress Syndrome (ARDS) Market Scope

The acute respiratory distress syndrome (ARDS) market is segmented on the basis of cause, type, route of administration, end user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cause

• Coronavirus Disease 2019 (COVID-19)
• Sepsis
• Inhalation of Harmful Substances
• Severe Pneumonia
• Others

Type

• Diagnosis
• Treatment

 Route of Administration

• Oral
• Parenteral
• Intramuscular
• Intravenous
• Others

 End User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Acute Respiratory Distress Syndrome (ARDS) Market Regional Analysis/Insights

The acute respiratory distress syndrome (ARDS) market is analyzed and market size insights and trends are provided by cause, type, route of administration, end user, distribution channel as referenced above.

The countries covered in the acute respiratory distress syndrome (ARDS) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the acute respiratory distress syndrome (ARDS) market because of recent technological advancements and the availability of numerous cutting-edge pharmacological molecules to improve the therapeutic process.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 as a result of an increase in biotechnology research and centre activity.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Acute Respiratory Distress Syndrome (ARDS) Market Share Analysis

The acute respiratory distress syndrome (ARDS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acute respiratory distress syndrome (ARDS) market.

Some of the major players operating in the acute respiratory distress syndrome (ARDS) market are:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd (India)
• Novartis AG (Switzerland)
• Drägerwerk AG & Co. KGaA (Germany)
• Fisher & Paykel Healthcare Limited (New Zealand)
• LivaNova PLC (U.K.)
• Besmed Health Business Corp. (Taiwan)
• Armstrong Medical (U.K.)
• Pfizer Inc. (U.S.)
• WEINMANN Emergency Medical Technology GmbH + Co. KG (Germany)
• Terumo Medical Corporation (U.S.)
• Getinge AB. (Sweden)
• EUROSETS (Italy)

SKU-59334